Target- |
MechanismCholesterol absorption inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismCholesterol absorption inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Effects on Lipids of 12 Weeks of 2 Doses of FM-VP4 in Subjects With Primary Hypercholesterolemia
The purpose of this study is to evaluate the safety and effects on lipids of FM-VP4 administered for 12 weeks in subjects with mild to moderate primary hypercholesterolemia.
100 Clinical Results associated with Forbes Medi-Tech Corp.
0 Patents (Medical) associated with Forbes Medi-Tech Corp.
100 Deals associated with Forbes Medi-Tech Corp.
100 Translational Medicine associated with Forbes Medi-Tech Corp.